CN1753680B - 用于治疗腹部不适的前列腺素衍生物 - Google Patents

用于治疗腹部不适的前列腺素衍生物 Download PDF

Info

Publication number
CN1753680B
CN1753680B CN2003801099014A CN200380109901A CN1753680B CN 1753680 B CN1753680 B CN 1753680B CN 2003801099014 A CN2003801099014 A CN 2003801099014A CN 200380109901 A CN200380109901 A CN 200380109901A CN 1753680 B CN1753680 B CN 1753680B
Authority
CN
China
Prior art keywords
prostaglandin
compound
purposes
dihydro
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2003801099014A
Other languages
English (en)
Chinese (zh)
Other versions
CN1753680A (zh
Inventor
上野隆司
久能祐子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32717850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1753680(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of CN1753680A publication Critical patent/CN1753680A/zh
Application granted granted Critical
Publication of CN1753680B publication Critical patent/CN1753680B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/56—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2003801099014A 2002-12-27 2003-12-26 用于治疗腹部不适的前列腺素衍生物 Expired - Lifetime CN1753680B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43646302P 2002-12-27 2002-12-27
US43646202P 2002-12-27 2002-12-27
US60/436,462 2002-12-27
US60/436,463 2002-12-27
PCT/JP2003/016857 WO2004060377A1 (en) 2002-12-27 2003-12-26 Derivatives of prostaglandins for treating abdominal discomfort

Publications (2)

Publication Number Publication Date
CN1753680A CN1753680A (zh) 2006-03-29
CN1753680B true CN1753680B (zh) 2010-12-08

Family

ID=32717850

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2003801099014A Expired - Lifetime CN1753680B (zh) 2002-12-27 2003-12-26 用于治疗腹部不适的前列腺素衍生物

Country Status (15)

Country Link
US (3) US7795312B2 (enExample)
EP (2) EP2281564A3 (enExample)
JP (2) JP4889219B2 (enExample)
KR (2) KR101164838B1 (enExample)
CN (1) CN1753680B (enExample)
AR (1) AR042670A1 (enExample)
AU (1) AU2003292556B2 (enExample)
BR (1) BRPI0317740B8 (enExample)
CA (1) CA2510051C (enExample)
ES (1) ES2591252T3 (enExample)
MX (1) MXPA05006981A (enExample)
NO (1) NO335441B1 (enExample)
NZ (1) NZ541110A (enExample)
TW (1) TWI336254B (enExample)
WO (1) WO2004060377A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
WO2004037268A1 (en) * 2002-10-23 2004-05-06 Sucampo Ag Prostaglandin compounds for the treatment of obesity
EP1641462B1 (en) * 2003-07-03 2010-11-24 Sucampo AG Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
CA2602812C (en) 2005-04-12 2014-11-18 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
JP5427029B2 (ja) 2006-09-06 2014-02-26 スキャンポ・アーゲー 消化管の重炭酸分泌を促進するための方法および組成物
US20080207759A1 (en) * 2007-02-27 2008-08-28 Sucampo Ag Method for protecting mitochondria
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
MX342548B (es) * 2009-09-18 2016-10-04 Merck Sharp & Dohme Corp * Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal.
IT1402047B1 (it) * 2010-10-19 2013-08-28 Cross Pharma Sa Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EP2841065A4 (en) * 2012-04-23 2015-09-16 Sucampo Ag METHOD FOR TREATING IRRITATION SYNDROME WITH RUNNING
SG10201705989YA (en) 2012-10-15 2017-08-30 Epizyme Inc Substituted benzene compounds
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3187438B2 (ja) 1996-06-10 2001-07-11 株式会社アールテック・ウエノ エンドセリン拮抗剤
US6046239A (en) * 1997-08-05 2000-04-04 American Home Products Corporation Anthranilic acid analogs
CA2279267C (en) * 1997-11-28 2010-01-12 R-Tech Ueno, Ltd. Use of 15-ketoprostaglandin e compounds as endothelin antagonist
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
EP1220849B1 (en) * 1999-10-15 2004-05-19 Sucampo AG Bicyclic compounds composition and method for stabilizing the same
JP4183943B2 (ja) * 2000-04-06 2008-11-19 スキャンポ・アーゲー １５−ケトプロスタグランジンを含む胆汁分泌促進剤組成物
US6414016B1 (en) * 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
PT1389116E (pt) * 2001-05-18 2008-04-11 Sucampo Ag Composição de indução catártica
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) * 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel

Also Published As

Publication number Publication date
US20040138308A1 (en) 2004-07-15
JP2006513232A (ja) 2006-04-20
MXPA05006981A (es) 2005-12-14
AR042670A1 (es) 2005-06-29
NZ541110A (en) 2008-11-28
WO2004060377A1 (en) 2004-07-22
AU2003292556A1 (en) 2004-07-29
EP1575596A1 (en) 2005-09-21
BR0317740A (pt) 2005-11-22
EP1575596B1 (en) 2016-06-22
JP2012031202A (ja) 2012-02-16
CN1753680A (zh) 2006-03-29
CA2510051A1 (en) 2004-07-22
CA2510051C (en) 2016-07-05
TWI336254B (en) 2011-01-21
AU2003292556B2 (en) 2009-09-10
NO20053623L (no) 2005-09-26
US20130217770A1 (en) 2013-08-22
JP4889219B2 (ja) 2012-03-07
EP2281564A2 (en) 2011-02-09
EP2281564A3 (en) 2012-09-05
NO20053623D0 (no) 2005-07-26
NO335441B1 (no) 2014-12-15
KR20120045051A (ko) 2012-05-08
BRPI0317740B8 (pt) 2021-05-25
KR101164838B1 (ko) 2012-07-11
US7795312B2 (en) 2010-09-14
US20100298424A1 (en) 2010-11-25
TW200418491A (en) 2004-10-01
BRPI0317740B1 (pt) 2018-09-18
ES2591252T3 (es) 2016-11-25
KR20050086950A (ko) 2005-08-30

Similar Documents

Publication Publication Date Title
US20100298424A1 (en) Method for treating abdominal discomfort
EP1392318B1 (en) 15-keto-prostaglandins for treating drug-induced constipation
AU2008271982B2 (en) Pharmaceutical combination of NSAID and prostaglandin compound
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
JP5294559B2 (ja) クロライドチャンネルオープナーとしてプロスタグランジンアナログを含む腸溶性組成物
JP4705782B2 (ja) 肥満の処置のためのプロスタグランジン化合物
CN101827598B (zh) 阿片样物质与前列腺素化合物的药物组合
TWI594751B (zh) 治療帶有腹瀉之腸躁症之方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20101208